Regional Phenotyping of CF and Non-CF Bronchiectasis

RecruitingOBSERVATIONAL
Enrollment

100

Participants

Timeline

Start Date

February 8, 2021

Primary Completion Date

March 31, 2026

Study Completion Date

March 31, 2027

Conditions
Cystic FibrosisNon-CF Bronchiectasis
Interventions
DRUG

Xenon

"Subjects will be scanned on a commercial 3T whole-body MRI scanner equipped with high-performance gradient systems. Natural isotopic abundance or isotopically-enriched xenon gas (\~86% 129Xe, Linde Inc.) will be used for all studies. Subjects will be positioned supine in the scanner with a 129Xe RF coil around their chests. Using conventional proton MRI and a breath-hold acquisition, scout images will be obtained to localize the subject for subsequent 129Xe acquisitions. 129Xe images will be acquired using the same breath-hold maneuver and a pulse sequence, covering the entire lung (acquisition time \<10 s, approximately 3-mm in-plane resolution, 15-mm slice thickness or less). Additional scans (sequences) may be performed. A maximum of 4 doses of 129Xe will be given throughout the study following the calibration dose."

Trial Locations (1)

45229

RECRUITING

Penny New, Cincinnati

All Listed Sponsors
lead

Children's Hospital Medical Center, Cincinnati

OTHER